Filing Flows › Biolargo (BLGO) › Q3 2025
Biolargo (BLGO) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 14, 2025
Biolargo (BLGO) reported revenue of $1.1M for the third quarter 2025 (Q3 2025), -75% from a year earlier and -60% from the quarter before. Operating margin was -651.0%, net loss $7.2M (656.8% of revenue).
Biolargo, Q3 2025: revenue $1.1M (-75% year over year), operating margin -651.0%, net loss $7.2M, operating cash flow −$2.8M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.1M | -60% | -75% |
| Operating profit | −$7.2M | — | — |
| Net earnings | −$7.2M | — | — |
| Operating cash flow | −$2.8M | — | — |
What changed
Revenue was $1.1M in Q3 2025, down 75% year over year and down 60% from the previous quarter. Product was the largest line at 70% of revenue. Product lost $3.2M year over year (down 80%), 97% of the total change.
Gross margin was 33.7%, down 5.9 points from a year earlier. Operating costs exceeded revenue by $7.2M, an operating margin of -651.0%. Operating expenses grew 171% against a revenue fall of 75%. The fastest-growing cost line was SG&A (+48%). The quarter ended with a net loss of $7.2M, wider than the previous quarter's $1.9M loss. Minority interests bore $765K of it: to shareholders the quarter was a loss of $6.5M.
Operating cash flow was −$2.8M. Non-cash charges added back $34K of depreciation and $844K of share-based compensation. Working capital and other items added $3.6M.
Questions
What was Biolargo's revenue in the third quarter 2025?
Biolargo (BLGO) reported revenue of $1.1M for the third quarter 2025 (Q3 2025), -75% from a year earlier and -60% from the quarter before.
Was Biolargo profitable in the third quarter 2025?
Operating loss was $7.2M (-651.0% of revenue) and net loss $7.2M.
Source: Biolargo 10-Q on SEC EDGAR.